Insider Buying: Diaceutics PLC (LON:DXRX) Insider Buys 113 Shares of Stock

Diaceutics PLC (LON:DXRX) insider Nick Roberts acquired 113 shares of Diaceutics stock in a transaction dated Wednesday, August 28th. The shares were bought at an average cost of GBX 134 ($1.77) per share, with a total value of £151.42 ($199.68).

Nick Roberts also recently made the following trade(s):

• On Friday, June 28th, Nick Roberts acquired 122 shares of Diaceutics stock. The shares were bought at an average cost of GBX 1 ($0.01) per share, with a total value of GBX 122 ($1.61).

Diaceutics Stock Performance

DXRX opened at GBX 132.50 ($1.75) on Friday. The firm has a market cap of £111.91 million, a PE ratio of -6,537.50 and a beta of 0.57. The business has a fifty day simple moving average of GBX 127.85 and a 200-day simple moving average of GBX 114.81. The company has a quick ratio of 9.92, a current ratio of 6.40 and a debt-to-equity ratio of 2.95. Diaceutics PLC has a fifty-two week low of GBX 82 ($1.08) and a fifty-two week high of GBX 136 ($1.79).

Analysts Set New Price Targets

Separately, Canaccord Genuity Group reissued a “buy” rating and set a GBX 160 ($2.11) price objective on shares of Diaceutics in a research note on Tuesday, August 20th.

About Diaceutics

Diaceutics PLC, a diagnostic commercialisation company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It operates DXRX platform, which offers DXRX data solutions, including access to various pipelines of diagnostic testing data from a network of laboratories that provides DXRX signal, lab mapping, testing dashboard, and physician mapping services; DXRX marketplace solutions, which enables a marketplace, where labs, pharma, and diagnostic companies come to find partners for collaborations on precision medicine diagnostics.